156 related articles for article (PubMed ID: 32744369)
41. Comparison of the efficacy and safety of using 0.01% versus 0.03% bimatoprost for the treatment of eyebrow hypotrichosis: A randomized, double-blind, split-face, comparative study.
Suchonwanit P; Harnchoowong S; Chanasumon N; Sriphojanart T
J Cosmet Dermatol; 2020 Mar; 19(3):714-719. PubMed ID: 31317662
[TBL] [Abstract][Full Text] [Related]
42. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
[TBL] [Abstract][Full Text] [Related]
43. Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus.
Taher ZA; Lauzon G; Maguiness S; Dytoc MT
Br J Dermatol; 2009 Sep; 161(3):654-9. PubMed ID: 19438859
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: a randomized controlled trial.
Alshiyab DM; Al-Qarqaz FA; Muhaidat JM; Alkhader YS; Al-Sheyab RF; Jafaar SI
J Dermatolog Treat; 2022 Feb; 33(1):146-149. PubMed ID: 32048900
[TBL] [Abstract][Full Text] [Related]
45. Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo.
Mina M; Elgarhy L; Al-Saeid H; Ibrahim Z
J Cosmet Dermatol; 2018 Oct; 17(5):744-751. PubMed ID: 29532621
[TBL] [Abstract][Full Text] [Related]
46. Topical Histamine Stimulates Repigmentation of Nonsegmental Vitiligo by a Receptor-Dependent Mechanism.
Liu J; Xu Y; Lin TK; Lv C; Elias PM; Man MQ
Skin Pharmacol Physiol; 2017; 30(3):139-145. PubMed ID: 28419984
[TBL] [Abstract][Full Text] [Related]
47. An open label study to compare the efficacy of topical mometasone furoate with topical placental extract versus topical mometasone furoate with topical tacrolimus in patients with vitiligo involving less than 10% body surface area.
Shrestha S; Jha AK; Thapa DP; Bhattarai CK; Ghimire A
Nepal Med Coll J; 2014 Sep; 16(1):1-4. PubMed ID: 25799800
[TBL] [Abstract][Full Text] [Related]
48. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo.
Ho N; Pope E; Weinstein M; Greenberg S; Webster C; Krafchik BR
Br J Dermatol; 2011 Sep; 165(3):626-32. PubMed ID: 21457214
[TBL] [Abstract][Full Text] [Related]
49. [Vitiligo. Treatment of 12 cases with topical tacrolimus].
Almeida P; Borrego L; Rodríguez-López J; Luján D; Cameselle D; Hernández B
Actas Dermosifiliogr; 2005 Apr; 96(3):159-63. PubMed ID: 16476357
[TBL] [Abstract][Full Text] [Related]
50. Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo.
Abd-Elazim NE; Yassa HA; Mahran AM
J Cosmet Dermatol; 2020 Jun; 19(6):1447-1455. PubMed ID: 31668003
[TBL] [Abstract][Full Text] [Related]
51. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
Hartmann A; Bröcker EB; Hamm H
J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
[TBL] [Abstract][Full Text] [Related]
53. Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial.
Zaky MS; Hashem OA; Mahfouz SM; Elsaie ML
Arch Dermatol Res; 2023 Nov; 315(9):2635-2641. PubMed ID: 37517060
[TBL] [Abstract][Full Text] [Related]
54. Combined microneedling with tacrolimus vs tacrolimus monotherapy for vitiligo treatment.
Ebrahim HM; Elkot R; Albalate W
J Dermatolog Treat; 2021 Dec; 32(8):999-1004. PubMed ID: 32041441
[TBL] [Abstract][Full Text] [Related]
55. Tacrolimus-induced hyperpigmentation in a patch of vitiligo.
De D; Kanwar AJ
Skinmed; 2008; 7(2):93-4. PubMed ID: 18327009
[TBL] [Abstract][Full Text] [Related]
56. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series.
Tanghetti EA
Cutis; 2003 Feb; 71(2):158-62. PubMed ID: 12635898
[TBL] [Abstract][Full Text] [Related]
57. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
Lepe V; Moncada B; Castanedo-Cazares JP; Torres-Alvarez MB; Ortiz CA; Torres-Rubalcava AB
Arch Dermatol; 2003 May; 139(5):581-5. PubMed ID: 12756094
[TBL] [Abstract][Full Text] [Related]
58. Assessing effectiveness of adding niosomal atorvastatin 1% ointment to topical calcineurin inhibitor treatment in non-segmental vitiligo.
Zartab H; Aflatoonian M; Shamsi-Meymandi S; Pardakhty A; Isazadeh A; Firooz A; Amiri R
J Cosmet Dermatol; 2024 Jun; 23(6):2103-2108. PubMed ID: 38348697
[TBL] [Abstract][Full Text] [Related]
59. Impacts of exposure to topical calcineurin inhibitors on metabolism in vitiligo infants.
Hu W; Lin F; Lei J; Xu AE
Pediatr Res; 2023 Feb; 93(3):661-665. PubMed ID: 35681095
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Bimatoprost 0.01% for the Treatment of Eyebrow Hypotrichosis: A Randomized, Double-Blind, Vehicle-Controlled Study.
Suchonwanit P; Chanasumon N; Sriphojanart T
Dermatol Surg; 2019 Dec; 45(12):1549-1556. PubMed ID: 30913051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
